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ABSTRACT
In current clinical practices, up to 27% of all breast cancer patients receive 
neoadjuvant chemotherapy. High pathological complete response rate is frequently 
associated with tumor-infiltrating lymphocytes. Additionally, circulating immune cells 
are also often linked to chemotherapy response. 
We performed a retrospective analysis on a cohort of 112 breast cancer patients 
(79 triple-negative, 33 hormone receptor-negative/HER2-positive) treated with 
standard neoadjuvant chemotherapy. Eosinophil and lymphocyte counts were 
collected from whole blood at baseline and during follow-ups and their associations 
with pathological complete response, relapse, disease-free and breast cancer-specific 
survival were analyzed.
We observed a higher pathological complete response rate in patients who 
presented at baseline a relative eosinophil count ≥ 1.5% (55.6%) than in those with a 
relative eosinophil count < 1.5% (36.2%)(p = 0.04). An improvement in breast cancer-
specific survival in patients with high relative eosinophil count (p = 0.05; HR = 0.336; 
95% CI = 0.107–1.058) or with high relative lymphocyte count (threshold = 17.5%, 
p = 0.01; HR = 0.217; 95% CI = 0.060–0.783) were also observed. Upon combining 
the two parameters into the eosinophil x lymphocyte product with a threshold at 35.8, 
associations with pathological complete response (p = 0.002), relapse (p = 0.028), 
disease-free survival (p = 0.012) and breast cancer-specific survival (p = 0.001) were 
also recorded.
In conclusion, the relative eosinophil count and eosinophil x lymphocyte product 
could be promising, affordable and accessible new biomarkers that are predictive 
for neoadjuvant chemotherapy response and prognostic for longer survival in triple-
negative and hormone receptors-negative/HER2-positive breast cancers. Confirmation 
of these results in a larger patient population is needed.
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INTRODUCTION
Breast cancer is the most common cancer and 
the leading cause of cancer-related death in women 
worldwide, with 1.67 million new cases and 522,000 
deaths each year [1]. Early breast cancer is usually treated 
with surgery, radiotherapy and adjuvant systemic therapy. 
Recently, neoadjuvant treatment has become the main 
strategy to turn inoperable tumors into operable tumors 
and to allow for more frequent conservative breast surgery. 
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Overall, approximately 7–27% of all new breast cancers 
in high-income countries are treated with neoadjuvant 
chemotherapy (NAC) treatment [2]. 
Pre-operative treatment allows rapid assessment 
of drug efficacy, and the pathological complete response 
(pCR) is commonly used as the endpoint for NAC trials. 
Evidence supporting the association between pCR and 
survival benefit has been previously demonstrated, 
especially for aggressive tumors such as triple-negative 
breast cancer (TNBC) and hormone receptor-negative/
HER2-positive (HR−/HER2+) cancer [3–6]. Indeed, higher 
pCR rates were observed for TNBC and HR−/HER2+ 
breast cancers compared to luminal subtypes. Moreover, 
such a higher pCR rate was also associated with a long-
term benefit [4, 7, 8]. 
There are currently no known factors predicting 
chemotherapy sensitivity in breast cancer. Recent 
reports have suggested a role for the immune system 
in chemotherapy response. Indeed, some studies 
demonstrated an association between tumor-infiltrating 
lymphocytes (TILs) and chemotherapy response [9–11]. In 
particular, TNBC and HR−/HER2+ breast cancers showed 
increased TIL scores compared to HR-positive breast 
cancers, and a high TIL score was associated with a higher 
pCR rate [8]. Most likely, the distinct TIL subpopulations 
contribute in a different manner in treatment response. 
As a matter of fact, Ladoire and colleagues described 
that pCR was associated with Treg depletion and an 
increase in the number of CD8+ T cells [12]. Furthermore, 
chemotherapy sensitivity and cancer outcomes both appear 
to be affected by circulating immune cells, including 
neutrophils, lymphocytes and eosinophils [13–17].
Bearing in mind the possible impact of the immune 
system on chemotherapy response, the aim of the current 
study was to analyze the potential use of pretreatment 
circulating eosinophil counts as a biomarker of therapy 
response in TNBC and HR−/HER2+ breast cancers treated 
with NAC. 
RESULTS
Patient characteristics and treatment
Overall, 112 early breast cancer patients treated 
with NAC at the University Hospital of Liege (CHU 
Liege) between December 2005 and November 2017 were 
included in the analysis. The median follow-up was 37.5 
months (range 9–156 months). The median age at diagnosis 
was 51.5 years (range 25–78 years). Seventy-nine patients 
(70.5%) had a TNBC, and 33 patients (29.5%) had an HR−/
HER2+ tumor. Patients were classified according to their 
HER2 status, Ki67 value, tumor size, lymph node status, 
tumor grading, histological subtype and lymphovascular 
invasion, as summarized in Table 1.
Seventy-one patients received Epirubicin-
Cyclophosphamide followed by Paclitaxel or Docetaxel; 8 
patients received Epirubicin-Cyclophosphamide followed 
by Carboplatin-Paclitaxel weekly; 27 patients received 
5-fluorouracil-Epirubicin-Cyclophosphamide followed by 
Paclitaxel or Docetaxel; 2 patients received 5-fluorouracil-
Epirubicin-Cyclophosphamide alone; 2 patients received 
Paclitaxel in monotherapy and 2 patients received 
Carboplatin-Paclitaxel or Docetaxel alone because of 
cardiac co-morbidity. Trastuzumab was administered in all 
33 HER2-positive patients. Overall, 99 patients received 
radiotherapy.
We observed a pCR in 51 of the 112 patients 
(45.5%). Relapse was observed in 23 cases (20.5%), breast 
cancer-related death was observed in 15 patients (13.4%), 
and 3 patients died from other causes.
Relative eosinophil and lymphocyte counts 
association with pCR
The primary endpoint of this study is to show a 
statistically significant association between baseline 
relative eosinophil count (REC) and pCR. 
Patients showing a pCR after neoadjuvant treatment 
had a higher median REC at baseline compared to 
patients who did not exhibit a pCR (median REC 1.9% 
and 1.2% respectively; Mann-Whitney test; p = 0.048). 
No statistically significant differences were observed for 
baseline relative lymphocyte count (RLC) (p = 0.184), 
absolute eosinophil count (p = 0.194) and absolute 
lymphocyte count (p = 0.630) (Figure 1).
Patients were classified for REC and RLC, using 
cut-offs of 1.5% and 17.5%, respectively, as in similar 
studies previously published [18, 19]. Overall, 54 patients 
had a REC ≥ 1.5% (48.2%) and 58 had a REC < 1.5% 
(51.8.%), showing a significant association between high 
REC and pCR in univariate analysis (Chi-Square test; 
p = 0.04). To explain, 30 of the 54 patients in the high REC 
group (55.6%) reached a pCR whereas only 21 of the 58 
patients in the group with a REC < 1.5% (36.2%) reached 
a pCR. Out of the 105 patients included in the high RLC 
group, 49 patients (46.7%) experienced a pCR, while only 
2 of the 7 patients in the low RLC group (28.6%) reached 
a pCR. This association between pCR and RLC was not 
statistically significant (p = 0.352). 
To perform multivariate analyses, univariate 
analyses were first calculated for all binary variables (Chi-
Square test) and continuous variables (Mann-Whitney 
U test) presented in Table 2. Next, a multiple regression 
analysis was performed using the variables with a 
univariate p value < 0.2. The results are shown in Table 2. 
We observed that a greater T stage is associated with a 
lower rate of pCR (OR = 3.286, 95% CI = 1.673–6.453; 
p = 0.001), while a high REC is predictive of pCR 
(OR = 0.343, 95% CI = 0.130–0.906; p = 0.031).
The primary end-point of the study was thus reached 
with a statistically significant positive association between 
REC and pCR, both in univariate or multivariate analyses.
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Table 1: Baseline characteristics of the 112 patients included in the analysis
N of patients (tot. 112) % of patients































































































































Relative eosinophil and lymphocyte counts 
association with relapse
We did not observe any statistically significant 
differences in the frequency of relapse between the low 
and high REC and RLC groups. We observed incidences 
of relapse of 16.7% and 24.1% in the groups with REC 
≥ 1.5% and REC < 1.5%, respectively (p = 0.328). 
Considering the lymphocytes, we observed an incidence of 
relapse of 19.1% in the group with RLC ≥ 17.5%, whereas 
42.9% of the group with RLC < 17.5% (p = 0.131) 
exhibited relapse. In a multiple regression analysis, 
performed with the variables showing a p value < 0.2 in 
univariate analysis, we observed a significant association 
with relapse for lymphovascular invasion (OR = 4.052, 
95% CI = 1.255–13.083; p = 0.019) and for N stage (OR = 
2.423, 95% CI = 1.201–4.886; p = 0.013) (Table 3).
Relative eosinophil and lymphocyte counts 
association with survival
Disease-free survival (DFS) and breast cancer-
specific survival (BCSS) were analyzed with respect 
to REC and RLC using the same thresholds mentioned 
above. A 3-year DFS rate of 86% was observed for patients 
with REC ≥ 1.5%, whereas the DFS rate for patients 
with REC < 1.5% was 73% (p = 0.205; HR = 0.585, 
95% CI = 0.252–1.358) (Figure 2A). For BCSS, we 
observed a statistically significant benefit for patients with 











NR: not reported; T: tumor size; N: lymph node status; G: tumor grade; pCR: pathological complete response; EC: 
Epirubicin-Cyclophosphamide; Ptx: Paclitaxel; CBDCA: Carboplatin; FEC: 5-fluorouracil-Epirubicin-Cyclophosphamide; 
Txt: Docetaxel.
Figure 1: Scatter dot plots for baseline REC, RLC, absolute eosinophil and lymphocyte counts in patients with or 
without a pCR. The comparisons between baseline distributions were calculated by the Mann-Whitney U test. (A) Scatter dot plot for 
baseline REC showing a median of 1.9% in patients experiencing a pCR vs 1.2% in patients without pCR (p = 0.048). (B) Scatter dot plot 
for baseline absolute eosinophil count showing a median of 0.13 × 103/mm3 in patients with pCR vs 0.09 × 103/mm3 in patients without pCR 
(p = 0.194). (C) Scatter dot plot for baseline RLC showing a median of 28.1% in patients experiencing a pCR vs 26.9% in patients without 
pCR (p = 0.184). (D) Scatter dot plot for baseline absolute lymphocyte count showing a median of 1.93 × 103/mm3 in patients experiencing 
a pCR vs 1.90 × 103/mm3 in patients without pCR (p = 0.630).
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with REC ≥ 1.5% compared to 80% for patients with REC 
< 1.5% (p = 0.050; HR = 0.336, 95% CI = 0.107–1.058) 
(Figure 2B). Likewise, we observed 3-year DFS rates of 
82% and 56% for patients with RLC ≥ 17.5% and < 17.5%, 
respectively (p = 0.079; HR = 0.351, 95% CI = 0.102–
1.200) and 3-year BCSS rates of 88% and 49% for high 
and low RLC, respectively (p = 0.010; HR = 0.217, 95% CI 
= 0.060–0.783) (Figure 2C and 2D). We chose to present 
the results according to cut-offs previously used in the 
literature for other diseases to standardize data reporting 
[18, 19]. However, the two thresholds used appear to be 
suboptimal cut-offs for separating the survival curves in 
breast cancer patients (Supplementary Figure 1). In fact, 
as shown in the Supplementary Materials, it is possible to 
maximize the results by calculating the cut-offs using the 
3 ROC curves for pCR, relapse and breast cancer-specific 
death. We hypothesized that the best cut-offs for REC and 
RLC can be calculated as the mean values of the 3 Yunden 
indexes calculated on the 3 ROC curves: 1.32% for REC 
and 24.68% for RLC (Supplementary Figure  2). 
Eosinophil-lymphocyte product (ELP)
We combined REC with RLC by calculating the 
product of their respective relative values, which we defined 
as the eosinophil-lymphocyte product (ELP). We first 
calculated the Receiver Operating Characteristic (ROC) 
curves for pCR, relapse and death. Next, the respective 
Table 2: Univariate and multivariate analysis for baseline circulating eosinophils and lymphocytes in association with 
















0.352 0.243 − − −
Baseline RLC − − 0.184† 0.643 −
Baseline absolute LYM − − 0.719 − −
Baseline REC 
(cut-off 1.5%)
0.04† * 0.502 − 0.031* 0.343
(0.130–0.906)
Baseline REC − − 0.048* − −
Baseline absolute EOS − − 0.194† 0.516 −
Ki67 % − − 0.685 − −
Ki67 (cut-off 20%) 0.436 0.315 − − −
HER2 0.216 0.458 − − −
Tumor size − − 0.009* − −
T 0.004† * 0.946 − 0.001* 3.286 
(1.673–6.453)
N 0.384 0.660 − − −
G 0.239 0.520 − − −
Histology 0.198† 0.281 − 0.417 −
Lymphovascular invasion 0.079† 0.479 − 0.806 −
Type of chemotherapy 0.171† 1.035 − 0.724 −
Age at diagnosis − − 0.171† 0.212 −
Age (cut-off 50 y) 0.411 0.497 − − −
†variable included in multiple regression analysis; *p value statistically significant
RLC: relative lymphocyte count; LYM: lymphocytes; REC: relative eosinophil count; EOS: eosinophils; T: T stage; N: 
lymph node status; G: grading.
Results of the univariate analysis performed by the Chi-Square test (discrete variables) or Mann-Whitney U test 
(continuous variables) for pCR using as variables the baseline relative lymphocyte and eosinophil counts, the baseline 
absolute lymphocyte and eosinophil counts, the Ki67, the HER2 status, the tumor size, the lymph node status, the tumor 
grade, the histological type, the lymphovascular invasion, the type of chemotherapy and the age at diagnosis. Multivariate 
analysis was performed by binary logistic regression including only the variables with a p value < 0.2 in the univariate test.
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Yunden indexes were calculated for each event. The mean 
value between the three found of 38.5 was selected as the 
cut-off for our analysis (Supplementary Figure 2).
Overall, 55 patients (49.1%) were classified in the 
group with ELP < 35.8, and 57 patients (50.9%) were 
classified in the group with ELP ≥ 35.8. 
Among the patient groups, a pCR was observed 
in 59.6% of patients with ELP ≥ 35.8 and in 30.9% of 
patients with ELP < 35.8, with a statistically significant 
association between these factors (Chi Square; p = 0.002). 
In multivariate analysis, ELP appears to be predictive for 
pCR (OR = 0.249, 95% CI = 0.092–0.669; p = 0.006), 
while a greater T stage is associated with a lower rate of 
pCR occurrence (OR = 3.118, 95% CI = 1.593–6.101; 
p = 0.001) (Table 4).
ELP is also predictive of relapse in univariate 
analysis, with a rate of relapse of 12.3% in patients with 
ELP ≥ 35.8 and 29.1% in patients with ELP < 35.8 (Chi 
Square; p = 0.028). In multivariate analysis, only nodal 
positivity is associated with an increased risk of relapse 
(OR = 2.969, 95% CI = 1.377–6.403; p = 0.006) (Table 5).
ELP is also a prognostic factor for survival, with 
3-year DFS rates of 90% and 69% for patients with high 
and low ELP, respectively (p = 0.012; HR = 0.337, 95% 

















0.131 0.243 − − −
Baseline RLC − − 0.267 − −
Baseline absolute LYM − − 0.048†* 0.303 −
Baseline REC 
(cut-off 1.5%)
0.328 0.502 − − −
Baseline REC − − 0.239 − −
Baseline absolute EOS − − 0.267 − −
Ki67 % − − 0.141† 0.403 −
Ki67 (cut-off 20%) 0.486 0.315 − − −
HER2 0.909 0.458 − − −
Tumor size − − 0.858 − −
T 0.137† 0.946 − 0.320 −
N 0.031†* 0.660 − 0.013* 2.423 
(1.201–4.886)
G 0.520 0.520 − − −
Histology 0.111† 0.281 − 0.303 −
Lymphovascular invasion 0.003†* 0.479 − 0.019* 4.052 
(1.255–13.083)
Type of chemotherapy 0.664 1.035 − − −
Radiotherapy 0.714 0.312 − − −
Age at diagnosis − − 0.385 − −−
Age (cut-off 50 y) 0.589 0.497 − − −
†variable included in multiple regression analysis; *p value statistically significant
RLC: relative lymphocyte count; LYM: lymphocytes; REC: relative eosinophil count; EOS: eosinophils; T: T stage; N: 
lymph node status; G: grading.
Results of the univariate analysis performed by the Chi-Square test (discrete variables) or Mann-Whitney U test 
(continuous variables) for relapse using as variables the baseline relative lymphocyte and eosinophil counts, the baseline 
absolute lymphocyte and eosinophil counts, the Ki67, the HER2 status, the tumor size, the lymph node status, the tumor 
grade, the histological type, the lymphovascular invasion, the type of chemotherapy, the radiotherapy and the age at 
diagnosis. Multivariate analysis was performed by binary logistic regression including only the variables with a p value  
< 0.2 in the univariate test.
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CI = 0.138–0.823). Further, we observed 3-year BCSS 
rates of 95% and 75% for patients with high and low ELP, 
respectively (p = 0.001; HR = 0.129, 95% CI = 0.029–0.573) 
(Figure 3).
Relative eosinophil and lymphocyte count during 
follow-up
At time points directly following surgery and during 
follow-up, we observed variations in lymphocyte and 
eosinophil counts. In particular, we observed an increase 
in REC from 1.4% at baseline to 2.7% after surgery and 
2.5% after 1-year of follow-up (Figure 4A). Conversely, 
we observed a decrease in RLC from 26.75% to 20.15% 
after surgery, but no difference between baseline and 
1-year follow-up (24.90%) (Figure 4C).
In the 23 patients who experienced a relapse, we 
observed statistically significant variations in REC from 
1.4% at baseline to 2.8% after surgery, and 1.7% at relapse 
(Figure 4B). No statistically significant variation was 
detected for RLC at relapse compared to the post-surgery 
time point (Figure 4D). Similar results were obtained 
from the absolute values of circulating eosinophils and 
lymphocytes (data not shown). 
Considering the values recorded after surgery, we 
observed a trend of association between REC and relapse, 
with a relapse rate of 18% in patients with REC ≥ 1.5% 
and 37.5% in patients with REC < 1.5% (Chi Square; 
p = 0.078). RLC is not associated with relapse (p = 0.574). 
Moreover, we observed a survival benefit in patients 
with high REC compared to those with low REC, with 
3-year DFS rates of 83% and 61% for high and low REC 
patients, respectively (p = 0.031; HR = 0.371, 95% CI = 
0.145–0.950). We further observed 3-year BCSS rates of 
89% and 65% for high and low REC patients, respectively 
(p = 0.004; HR = 0.243, 95% CI = 0.086–0.683). 
Figure 2: Kaplan Meier curves for DFS and BCSS according to baseline REC and RLC. Kaplan Meier curves were drawn 
using: (A) REC baseline with 1.5% threshold and DFS. (B) REC baseline with 1.5% threshold and BCSS. (C) RLC baseline with 17.5% 
threshold and DFS. (D) RLC baseline with 17.5% threshold and BCSS. P values were calculated with the Log-Rank test.
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Conversely, post-surgery RLC is not associated with DFS 
(p = 0.483; HR = 0.737, 95% CI = 0.312–1.710) or BCSS 
(p = 0.685; HR = 0.801, 95% CI = 0.274–2.346) (Figure 5).
DISCUSSION
In the current study, we analyzed the effect of 
eosinophils and lymphocytes on response to neoadjuvant 
chemotherapy and survival in HR-/HER2+ breast cancer. 
We observed a significant association between higher 
REC and pCR, but not between RLC and pCR. In terms 
of survival, we observed a significantly longer survival 
period for patients with higher REC and higher RLC, with 
the most important differences observed using the ELP, 
a combined index incorporating the relative eosinophil 
and lymphocyte counts. Our analyses focused on HR−/
HER2+ and TNBC subtypes for two reasons: first, the 
immune system has a key role in response to NAC; 
second, pCR is commonly used as a surrogate endpoint 
of survival for these more aggressive tumors [8, 20].
A simple blood analysis could reveal the status 
of the whole immune system, with circulating immune 
dysfunction probably linked to intra-tumoral immune 
inhibition or to an impaired ability of T cells to mount 
an anti-tumor immune response [21]. Different studies 
have demonstrated the association between blood cell 
counts and outcomes in several cancer types. In breast 
cancer, pretreatment lymphopenia was associated with 
poor survival and was predictive of tumor recurrence, 
and a higher absolute lymphocyte count predicted lower 
mortality in TNBC [13, 14, 22]. Similarly, the neutrophil/
lymphocyte ratio (NLR) and the platelet/lymphocyte ratio 
(PLR) were described to have prognostic value in breast 
cancer [21–31]. To the best of our knowledge, circulating 
eosinophil counts have been reported by two studies in 
the literature of breast tumors. Gunduz and colleagues 
observed a survival benefit for patients with lower baseline 
eosinophil counts in a cohort of 62 HER2+ breast cancers 
treated with adjuvant trastuzumab [15]. Conversely, 
Ownby and colleagues described a positive association 
between high baseline eosinophil counts and lower 
recurrence rates (2-year DFS rate, 21 ± 2% vs 34 ± 8%, 
p < 0.02) in 419 patients, of all subtypes [14]. Better 
known is the impact of peripheral eosinophil count 
in melanoma patients treated with immunotherapy. 
Associations linking both high baseline eosinophil counts 

















0.002 †* 0.285 − 0.006* 0.249 
(0.092−0.669)
ELP − − 0.025* − −
Ki67 % − − 0.685 − −
Ki67 (cut-off 20%) 0.315 0.315 − − −
HER2 0.216 0.458 − − −
Tumor size − − 0.009* − −
T 0.004†* 0.946 − 0.001* 3.118 
(1.593−6.101)
N 0.384 0.660 − − −
G 0.239 0.520 − − −
Histology 0.198† 0.281 − 0.374 −
Lymphovascular invasion 0.079† 0.479 − 0.822 −
Type of chemotherapy 0.171† 1.035 − 0.617 −
Age at diagnosis − − 0.171† 0.102 −
Age (cut-off 50 y) 0.411 0.497 − − −
†variable included in multiple regression analysis; *p value statistically significant
ELP: eosinophil-lymphocyte product; T: T stage; N: lymph node status; G: grading.
Results of the univariate analysis performed by the Chi-Square test (discrete variables) or Mann–Whitney U test (continuous variables) 
for pCR using as variables the ELP, the Ki67, the HER2 status, the tumor size, the lymph node status, the tumor grade, the histological 
type, the lymphovascular invasion, the type of chemotherapy and the age at diagnosis. Multivariate analysis was performed by binary 
logistic regression including only the variables with a p value < 0.2 in the univariate test. 
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and increased counts during treatment, with both improved 
treatment response and increased survival rates, were 
observed [18, 19, 32–34]. Additionally, one report of an 
immunotherapy-induced increase in eosinophil count was 
published for lung cancer patients, but no efficacy data 
were presented [35].
Figure 3: Kaplan–Meier curves for DFS and BCSS according to ELP. Kaplan–Meier curves were drawn using: (A) ELP baseline 
with 35.8% threshold and DFS. (B) ELP baseline with 35.8% threshold and BCSS. P values were calculated with the Log-Rank test.
















0.028†* 0.285 − 0.054 0.274 
(0.073–1.025)
ELP − − 0.173 − −
Ki67 % − − 0.141† 0.341 −
Ki67 (cut-off 20%) 0.486 0.315 − − −
HER2 0.909 0.458 − − −
Tumor size − − 0.858 − −
T 0.137† 0.946 − 0.437 −
N 0.031†* 0.660 − 0.006* 2.969 
(1.377–6.403)
G 0.520 0.520 − − −
Histology 0.111† 0.281 − 0.334 −
Lymphovascular invasion 0.003†* 0.479 − 0.06 3.218 
(0.953–10.866)
Type of chemotherapy 0.664 1.035 − − −
Radiotherapy 0.714 0.312 − − −
Age at diagnosis − − 0.385 − −−
Age (cut-off 50 y) 0.589 0.497 − − −
†variable included in multiple regression analysis; *p value statistically significant.
ELP: eosinophil-lymphocyte product; T: T stage; N: lymph node status; G: grading.
Results of the univariate analysis performed by the Chi-Square test (discrete variables) or Mann-Whitney U test 
(continuous variables) for relapse using as variables the baseline ELP, the Ki67, the HER2 status, the tumor size, the 
lymph node status, the tumor grade, the histological type, the lymphovascular invasion, the type of chemotherapy, the 
radiotherapy and the age at diagnosis. Multivariate analysis was performed by binary logistic regression including only the 
variables with a p value < 0.2 in the univariate test.
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Figure 4: Scatter dot plots for REC and RLC after surgery, after 1 year of follow-up and at relapse. (A) Scatter dot plot 
for baseline REC in the entire cohort showing a median of 1.4% at baseline vs 2.7% after surgery and 2.5% after 1-year of follow-up. (B) 
Scatter dot plot for baseline REC in 23 patients experiencing a relapse showing a median of 1.4% at baseline vs 2.8% after surgery and 
1.7% at relapse. (C) Scatter dot plot for baseline RLC in the entire cohort showing a median of 26.75% at baseline vs 20.15% after surgery 
and 24.90% after 1-year of follow-up. (D) Scatter dot plot for baseline RLC in 23 patients experiencing a relapse showing a median of 
23.3% at baseline vs 19.7% after surgery and 17% at relapse. The comparisons between baseline REC and RLC values in the 3 conditions 
were performed by Friedman tests (FT - upper line of p values) followed by Dunn post-hoc tests to compare conditions by pairs (DT - lower 
lines of p values). The corresponding significant p values are reported in each panel. ***= pval ≤ 0.0001; **= pval ≤ 0.001.
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Only one study analyzing circulating lymphocytes 
after neoadjuvant chemotherapy and surgery in breast 
cancer patients was found in the literature, while no data 
about eosinophils were reported. Beitsch and colleagues 
studied 15 early breast cancer patients, observing an 
impairment of natural killer (NK) cell activity with 
neither decreased NK cells number, nor changes in the 
percentage of T helper and suppressor cells [36]. In our 
study, we observed a decrease in circulating lymphocyte 
numbers after primary treatment without significant 
variation at relapse. No significant impact on survival for 
post-surgery RLC was detected. Conversely, we observed 
an increase in circulating eosinophil number after surgery 
and a significant reduction at relapse. Higher post-surgery 
REC was shown to be prognostic for DFS and BCSS, 
in accordance with baseline values. This observation 
suggests a role of tumor presence on peripheral eosinophil 
count, that could be linked to tumor infiltration by 
eosinophils or to a modification of tumor-induced immune 
cell differentiation.
Eosinophils are considered multifunctional cells 
that act by inducing tumor lysis or modulating immune 
responses [37]. Recent studies suggested that tumor-
infiltrating eosinophils secrete chemoattractant cytokines 
that guide CD8+ T cells into cancer tissue and induce 
normalization of the tumor vasculature [38]. Moreover, 
eosinophils act as antigen-presenting cells (APCs) via 
surface expression of the major histocompatibility complex 
I and II (MHC) receptors or by directly stimulating T cells 
through the expression of costimulatory molecules such as 
CD86, CD40, CD40L and CD28 [37, 39, 40]. Although 
some studies have analyzed the role of tumor-associated 
tissue eosinophilia (TATE), less is known about the role of 
circulating eosinophils, and their trafficking between the 
circulating and tumoral compartments. However, peripheral 
eosinophils and a combined index between eosinophils 
and lymphocytes, such as the proposed ELP, could be 
considered biomarkers predictive of NAC response and 
prognostic for increased survival. In the current study, 
the number of patients, the short follow-up time and the 
subsequent number of events registered are important 
limitations to draw definitive conclusions. Additional 
studies must be performed to confirm our results and to 
understand the mechanism by which circulating eosinophils 
affect patient prognosis, with the goal of exploiting this 
natural anticancer mechanism to personalize patient 
treatment. It is worth noting that the low number of events 
reported did not fulfill the requirements for the parametric 
Figure 5: Kaplan-Meier curves for DFS and BCSS according to post-surgery REC and RLC. Kaplan Meier curves were 
drawn using: (A) REC post-surgery with 1.5% threshold and DFS. (B) REC post-surgery with 1.5% threshold and BCSS. (C) RLC post-
surgery with 17.5% threshold and DFS. (D) RLC post-surgery with 17.5% threshold and BCSS. P values were calculated with Log-Rank test.
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Cox regression. Therefore, a non-significant value was 
obtained while calculating the risk of death between the 
low and high eosinophil groups. Such results underline 
the importance of conducting a long-term follow-up to 
measure the association between eosinophil counts and 
BCSS. Nevertheless, these results are encouraging due to 
the survival of many patients with high eosinophil rates by 
the 3-year follow-up. The innovative aspect of our study 
is to propose a new, affordable and accessible biomarker 
predictive of treatment response and prognostic for survival 
for TNBC and HR−/HER2+ breast cancers. 
MATERIALS AND METHODS
Patient selection and treatment
The current study is a retrospective analysis of a cohort 
of early breast cancer patients treated with neoadjuvant 
chemotherapy at CHU Liege between December 2005 and 
November 2017. The data cut-off is July 2018. 
All selected patients were women, in good 
Performance Status (PS 0–2) and with adequate organ 
function prior to the beginning of treatment. Only HR−/
HER2+ and TNBC patients were included in this analysis. 
All enrolled patients received neoadjuvant 
chemotherapy with different drugs according to physician 
choice (including Epirubicin, Cyclophosphamide, 
Paclitaxel/Docetaxel, Carboplatinum, 5-Fluorouracil and/
or Trastuzumab) and taking into account HER2 status. 
Chemotherapy was followed by surgery with or without 
radiotherapy. 
The total number of circulating eosinophils and 
lymphocytes were assessed before starting treatment, after 
surgery, after 1-year of follow-up and at relapse. Cut-offs 
of 1.5% for REC and 17.5% for RLC were used, according 
to similar studies conducted in melanoma patients, which 
used an optimization algorithm to identify the thresholds 
required to obtain the most significant relation with OS 
through a Log-Rank test [18, 19, 41].
The pCR was evaluated on histological samples, 
after surgery (ypT0N0 following the AJCC-UICC 
classification). The follow-up was done according to 
standard clinical practices and the relapse was defined 
as evidence of disease recurrence using imaging and/or 
histological analyses. DFS is defined as the length of 
time between the end of the primary treatment and the 
evidence of cancer recurrence. BCSS is considered as the 
length of time between diagnosis and death from breast 
cancer. 
The primary endpoint of this analysis was to 
evaluate the association between baseline REC and pCR. 
The secondary endpoints were to evaluate: the association 
between baseline RLC and pCR; the association between 
baseline and post-surgery REC or RLC and relapse; the 
median absolute values and median relative values of 
eosinophils and lymphocytes in patients with and without 
pCR; the variations in eosinophil and lymphocyte counts 
after surgery, at follow-up and at relapse; and the 3-year 
DFS and BCSS rates and respective HR according REC, 
RLC and ELP.
This study was conducted in accordance with the 
Declaration of Helsinki, and the institutional ethics 
committee approved the protocols. 
Statistical analysis
Statistical analyses and graphs were done using IBM 
SPSS Statistic v24 and GraphPad Prism 5. 
Univariate analyses: Pearson Chi-Squared tests 
were used to calculate the associations between tumor 
response to neoadjuvant chemotherapy and relapse with 
the following discrete variables: baseline and post-surgery 
REC (threshold = 1.5%) and RLC (threshold = 17.5%), 
baseline ELP (threshold=35.8%), HER2 status, Ki67 
(threshold = 20%), tumor stage, lymph node status, tumor 
grade, histological type, lymphovascular invasion, age at 
diagnosis (threshold = 50 years), types of chemotherapy 
and radiotherapy (only for relapse analysis). Mann–
Whitney U tests were used to calculate the associations 
between tumor response to neoadjuvant chemotherapy and 
relapse with the following continuous variables: baseline 
relative lymphocyte and eosinophil counts, baseline 
absolute lymphocyte and eosinophil counts, ELP, tumor 
size, Ki67 and age at diagnosis. 
Multivariate analyses: sequential binary logistic 
regression with forward stepwise selection of variables 
based on likelihood ratio were performed for both 
response and relapse, considering as dependent variables 
only the factors showing a p value < 0.2 in the Chi Square 
test or Mann-Whitney test. Some variables were tested as 
continuous and discrete variables (i.e. : Ki67), and when 
the p value was < 0.2 in both cases, the variable with the 
best p value was selected for multivariate analysis.
Kaplan Meier and Log-Rank tests were used to 
analyze survival. The Cox Regression Hazard model was 
used to calculate the HR for both DFS and BCSS. The 
3-year DFS and BCSS were calculated from the survival 
tables.
To evaluate the differences in the REC and RLC 
distributions during follow-up, we used a Friedman test 
comparing the three following conditions: baseline vs 
post-surgery vs 1-year follow-up. For the 23 patients 
showing a recurrence, the same test was used to compare 
the REC and RLC values at baseline vs post-surgery 
vs relapse time. The Friedman tests were followed by 
Dunn multiple comparison post-hoc tests to compare all 
conditions by pairs.
To select the best cut-off for ELP, the ROC curves 
for pCR, relapse and death were drawn. The best cut-off 
for each variable was calculated using the Yunden index, 
and the threshold selected for our analysis was the mean 
value between the three cut-offs calculated. 
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